

Hilda Angela Mujuru,¹ Renate Strehlau,² Pope Kosalaraksa,³ Rory Leisegang,⁴ Shaolan Shirley Xiang,⁴ Vinicius Vieira,⁴ Kathryn Kersey,⁴ Kulkanya Chokephaibulkit,⁵ Natella Rakhmanina⁶

¹Child and Adolescent Health Unit, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe; ²VIDA-Nkanyenzi Research Unit, Department of Paediatrics and Child Health, University of the Witwatersrand, Johannesburg, South Africa; ³Department of Pediatrics, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand; ⁴Gilead Sciences, Inc., Foster City, CA, US; ⁵Division of Infectious Diseases, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; ⁶The George Washington University and Children's National Hospital, Washington, DC, US

Introduction


- F/TAF is a co-formulated once-daily tablet and is a guideline-recommended dual NRTI in children ≥ 14 kg when used with an INSTI or NNRTI¹
- Although current WHO guidelines recommend an INSTI-based regimen with NRTI backbone as a first-line treatment in children and adolescents, some individuals can experience INSTI-associated toxicity, drug resistance and, ultimately, treatment failure^{2,3}
- The PI DRV is recommended as an alternative second-line treatment in children and infants aged ≥ 3 years, and COBI is a PK enhancer with no antiviral activity that can be easily co-formulated with antiretroviral therapy^{1,4}
- There are limited data on the PKs, safety and efficacy of COBI-boosted PIs in the pediatric population, including F/TAF with boosted PIs in young children
- GS-US-216-0128 is a multicenter, open-label, multicohort Phase 2/3 study evaluating the PKs, safety and efficacy of F/TAF plus ATV or DRV boosted with COBI (ATV/c and DRV/c, respectively) in virologically suppressed pediatric participants with HIV (NCT02016924)

Objectives

- This is an interim analysis to evaluate the PKs, safety and efficacy of F/TAF plus DRV/c in virologically suppressed children aged ≥ 3 years and weighing 14 to < 25 kg from Cohort 3 of study GS-US-216-0128

Methods

Figure 1. Study Design



*Enrollment: South Africa (n = 2) and Zimbabwe (n = 7)

Study Assessments

- Efficacy (virologic and immunologic) outcomes:** Plasma HIV-1 RNA and relative/absolute CD4 cell count
- PK outcomes:** iPK samples to examine steady-state exposures of DRV, COBI, FTC, TAF and TFV, including AUC_{tau}, C_{max} and C_{tau}
- Safety and tolerability outcomes:** AEs and clinical laboratory assessment, including chemistry and hematologic profiles

Results

Table 1. Baseline Demographics and Disease Characteristics

	Cohort 3: F/TAF + DRV/c (N = 9)
Median age, years (Q1, Q3)	4 (3, 6)
Female, n (%)	5 (56)
Median weight, kg (Q1, Q3)	16 (16, 17)
Median weight, Z-scores (Q1, Q3)	-0.4 (-1.7, +0.1)
Median height, Z-scores (Q1, Q3)	-0.8 (-1.7, +0.3)
Race, n (%)	
Black	2 (22)
Other	7 (78)
Hispanic or Latinx ethnicity, n (%)	0
HIV-1 RNA < 50 c/mL, n (%)	9 (100)
Median CD4 count, cells/μL (Q1, Q3)	1,237 (844, 1,490)
Median CD4, % (Q1, Q3)	41 (35, 42)
Vertical transmission, n (%)	9 (100)
Median eGFR _{Schwartz} [†] , mL/min/1.73 m ² (Q1, Q3)	166 (144, 169)
Baseline third agent, n (%)	
LPV/r	7 (78)
EFV	2 (22)

Duration of Exposure

- Median (Q1, Q3) duration of exposure: 66 weeks (63, 72), N = 9

Efficacy Outcomes

Figure 2. Virologic: HIV-1 RNA < 50 c/mL (Missing = Failure analysis)*




Figure 3. Immunologic: Change From Baseline in Absolute CD4 Cell Count





Figure 4. Immunologic: Change From Baseline in Relative CD4



Pharmacokinetic Outcomes

Table 2. Mean Exposures

	DRV (n = 9)	COBI (n = 8)	FTC (n = 8)	TAF (n = 8)	TFV (n = 8)
DRV/c Cohort 3 (N = 9)					
AUC _{tau} (h*ng/mL)	141,700	14,659	26,020	NA (AUC _{last} : 349)	1,159
C _{max} (ng/mL)	14,400	2,141	4,540	405	66
C _{tau} (ng/mL)	2,796	42	91	NA	37
Adult DRV/COBI/F/TAF ⁵					
AUC _{24h} (h*ng/mL)	87,909*	8,745†	11,918‡	132*	339‡
C _{max} (ng/mL)	8,826‡	1,129‡	2,056‡	163‡	19‡
C _{0h} (ng/mL)	1,899*	31‡	93‡	NA	12‡

*From population PK analysis in Phase 3 study of DRV/COBI/F/TAF (TMC114FD2HTX3001) in ARV-naïve participants (N = 355); †From population PK analysis in Phase 3 study of DRV/COBI/F/TAF (TM114IFD3013) in ARV-experienced participants; ‡From Phase 2 PK substudy (N = 21) GS-US-299-0102

- Preliminary analysis based on limited PK data
- Limitation: Comparison between exposures from noncompartmental analyses (pediatric) and population PK analysis (adult)

Overall Safety

Table 3. Adverse Events

Adverse Events, n (%)	Cohort 3: F/TAF + DRV/c (N = 9)
Any AE	9 (100)
AE occurring in > 1 participant	
Iron-deficiency anemia	2 (22)
Vomiting	3 (33)
Drug-related AEs	
Tinea capitis	1 (11)*
Vomiting	1 (11)*
Serious AE	0
Drug-related serious AE	0
AE leading to premature discontinuation	0
Death	0

*Considered by the investigator to be related to the study drugs

- All AEs were mild or moderate in severity

Laboratory Abnormalities

- Most treatment-emergent laboratory abnormalities were Grade 1 (2 [22%]) or 2 (6 [67%])
- One participant had two Grade 3 laboratory abnormalities at Week 4 of hypomagnesemia (0.83 mg/dL) and hyperkalemia (6.6 mEq/L); both were transient and resolved by Week 8

Abbreviations: ARV, antiretroviral; AE, adverse event; ATV, atazanavir; AUC_{24h}, area under the curve up to 24 hours; AUC_{tau}, area under the curve up to the last measurable concentration; AUC_{last}, area under concentration vs. time curve over dosing interval; c or COBI, cobicistat; C_{0h}, initial concentration; C_{max}, maximum observed plasma drug concentration; C_{tau}, observed drug concentration at end of dosing interval; DRV, darunavir; EFV, efavirenz; eGFR_{Schwartz}, estimated glomerular filtration rate by Schwartz equation; F or FTC, emtricitabine; GLSM, geometric least squares mean; IDMC, independent data monitoring committee; INSTI, integrase strand transfer inhibitor; iPK, intensive pharmacokinetic; LPV, lopinavir; mEq, milliequivalent; NA, not applicable; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic; Q, quartile; r, ritonavir; TAF, tenofovir alafenamide; TFV, tenofovir

Figure 5. Change From Baseline in eGFR_{Schwartz}





Figure 6. Change From Baseline in Serum Creatinine



Conclusions

- Interim data in virologically suppressed children aged ≥ 3 years and weighing between 14 and < 25 kg:
 - DRV, COBI, FTC, TAF and TFV exposures were within the range of exposures observed in adult studies
 - F/TAF plus DRV/c maintained viral suppression through 48 weeks of treatment
 - F/TAF plus DRV/c was well tolerated with no serious AEs or AEs that led to discontinuation or death
- To date, findings support the continuing evaluation of F/TAF as the NRTI backbone in combination with DRV/c in children with HIV

Next Steps

- Enrollment is ongoing in Cohorts 2 (≥ 6 to < 12 years; ≥ 25 to < 35 kg) and 3 (≥ 3 years; 14 to < 25 kg) to complete evaluation of F/TAF plus ATV or DRV boosted with COBI
- Population PK models will be developed once cohorts are fully enrolled to facilitate more appropriate comparisons
- Tablet-for-oral-suspension formulations of F/TAF and COBI have been developed; this formulation, with or without PI, is being evaluated for efficacy and safety in children aged ≥ 4 weeks and weighing ≥ 3 kg

References: 1. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Available at: <https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/pediatric-arv/guidelines-pediatric-arv.pdf> (accessed Jan 2023); 2. Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring: Recommendations for a Public Health Approach. Geneva: World Health Organization; 2021; 3. Zhao AV, et al. Retrovirology 2022;19:22; 4. Clinicalinfo.HIV.gov. Drug database: Cobicistat. June 2022. Available at: <https://clinicalinfo.hiv.gov/en/drugs/cobicistat/patient> (accessed Jan 2023); 5. F/TAF + DRV/c USPI 2018. Available at: <https://www.accessdata.fda.gov> (accessed Jan 2023)

Disclosures: HAM, RS, PK, KC and NR: no relevant disclosures; RL, SSX, VV and KK: employees of Gilead and own shares in Gilead.

Acknowledgments: We extend our thanks to the participants, their families and all study investigators and staff. Medical writing support was provided by Emma McConnell, PhD, and Olivia Morris, PhD (Aspire Scientific Ltd), and funded by Gilead.